双联抗血小板治疗非心源性缺血性脑卒中的疗效

Effect of dual antiplatelet therapy in the treatment of non-cardiogenic ischemic stroke

目的探究双联抗血小板治疗非心源性缺血性脑卒中的临床疗效。方法选择我院2017年1月至2017年12月收治的78例非心源性缺血性脑卒中患者为研究对象,将其随机分成对照组和研究组,每组39例。对照组采用阿司匹林治疗,研究组采用双联抗血小板治疗,对比两组治疗效果。结果治疗后,两组患者血小板聚集率、神经缺损评分均明显降低,且研究组低于对照组(P<0.05)。治疗期间,研究组患者不良反应总发生率和治疗总有效率均优于对照组(P<0.05)。结论双联抗血小板用于非心源性缺血性脑卒中患者,既可以降低治疗期间毒副反应发生率又能降低血小板聚集,同时还能提升患者整体治疗效果,是一种安全、高效的治疗方案。

Objective To explore the clinical efficacy of dual antiplatelet therapy in the treatment of non-cardiogenic ischemic stroke. Methods A total of 78 patients with non-cardiogenic ischemic stroke admitted in our hospital from January 2017 to December 2017 were selected as objects, they were randomly divided into control group and study group, with 39 cases in each group. The control group was treated with aspirin, and the study group was given dual antiplatelet therapy, the treatment effects of the two groups were compared. Results After treatment, the platelet aggregation rate and nerve defect scores in the both groups significantly decreased, and those in the study group were lower than the control group （P〈0.05）. The total incidence of adverse reactions and total effective rate in the study group were significantly better than those of the control group during the treatment （P〈0.05）. Conclusion Using dual antiplatelet therapy in patients with non-cardiogenic ischemic stroke can not only effectively decreased the platelet aggregation, but also decrease the incidence of toxic and side effects during treatment, and can improve the treatment effect of patients at the same time. Therefore, it is a safe and effective treatment program.